Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 16Thoracic 6Head & Neck 6Gynecologic 4Gastrointestinal 4Genitourinary 3Breast 2Sarcoma 1Endocrine 1

Conditions

Breast Neoplasms 96Triple Negative Breast Neoplasms 42Breast Neoplasms, Male 18Inflammatory Breast Neoplasms 11Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Stomach Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Sarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Testicular Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Neoplasms, Unknown Primary 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Carcinoma In Situ 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Thrombocytosis 1

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Taxes × Breast × Clear all
NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Active not recruiting
94 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡